US 10,406,366 B2Grant
Transvenous phrenic nerve stimulation system
Issue Date:2019-09-10
•18 Claims
•5 Drawing Sheets
Abstract
A lead system and method of use for treating breathing disorders by the transvenous stimulation of the phrenic nerve. The lead is implanted in a vein near one portion of the phrenic nerve.
Metadata
Assignee
- RESPICARDIA, INC.
Inventors
- Randy W. Westlund
- Mark Gelfand
Application Information
Application Number:US 12/150,654
Filing Date:2008-04-30
Priority Date:2006-11-17
Art Unit:3792
Classifications
IPC:
A61N1/36A61N1/05A61N1/368
Field of Search:
A61N 1/05A61N 1/0558A61N 1/3601A61N 1/3611A61N 1/3684A61N 1/0551
Patent Drawings (5 sheets)
Description
Cross Reference to Related Cases
[0001] The present case claims the benefit of and incorporates by reference U.S. Provisional Application 60/926,910 filed Apr. 30, 2007 entitled “Leads for Transvenous Phrenic Stimulation”. The present case also claims the benefit of and incorporates by reference and is a continuation-in-part of U.S. Utility application Ser. No. 11/601,150 filed Nov. 17, 2006 now U.S. Pat. No. 8,244,359 entitled “System and Method to Modulate Phrenic Nerve to Prevent Sleep Apnea”.
Field of the Invention
[0002] The present invention relates generally to a method of implanting a phrenic nerve stimulation lead system and a related phrenic nerve stimulation lead for use with an implanted pulse generator (IPG) for treating a breathing disorder.
Background of the Invention
[0003] Many patients with breathing disorders such as central sleep apnea (CSA) display periods of rapid respiration followed by a relatively long compensatory pause in respiration. The clinical manifestation of the disorder is a period of shallow rapid breathing followed by frank apnea or hypopnea. This pattern repeats episodically and is called Cheyne Stokes Respiration (CSR). Several treatment regimes have been proposed to alleviate CSR, including a technique presented in detail in the utility application incorporated by reference.
[0004] Historically, the ability to control respiration via phrenic nerve stimulation is widely known and well reported in the literature. Early work shows the use of phrenic nerve stimulation to treat paralyzed patients to initiate and support respiration. A substantial body of animal research discloses the basic mechanisms for respiration control though stimulation of the phrenic nerve.
[0005] Although phrenic nerve stimulation is known in the art there is a continuing need to improve the “leads” devices for accessing and electrically stimulating the phrenic nerve. And there is a continuing need to improve the stimulation methodology.
Summary of the Invention
[0006] The phrenic nerve stimulation lead device has a flexible elongate lead body with a proximal connector and a distal tip. In use the lead is permanently implanted in a vein near one portion of the phrenic nerve. The lead has physical features and properties important for successful transvenous deployment and stimulation of the phrenic nerve from the left pericardiophrenic vein.
[0007] The stimulation lead has a distal tip tapered into a “rats tail”. The presence of this extended tapered section will serve to orient and stabilize the lead and the electrodes in the vessel by restricting movement of the lead with respect to the vessel. The additional surface area of the lead provides additional friction and ensures that the vessel and lead do not move relative to each other. One or more and preferably two electrode sites are placed proximal of this distal tip. Each electrode is typically formed as a ring and individually electrically coupled to the proximal connector by internal conductors within the lead.
[0008] In one embodiment a guidewire lumen is carried entirely through the lead body and the lumen is concentric with the distal tip at the distal tip. In an alternate embodiment the lead is stiffened by a removable stylet that is inserted into the lead into a stylet lumen.
[0009] An optional mechanical stop feature may be included within the lead body to intercept and interact with a finishing guide wire to stabilize the lead during placement.
[0010] The lead is acutely repositionable but anticipated foreign-body response will render it permanent in the vessel. The lead may have steroid eluting features to regulate this physiologic process.
[0011] The shape of the lead body includes two or more curves, bends or loops near the distal end of the lead. These curves in the lead body lie in two planes and direct the tip at an angle. These features stabilize the lead in a large companion vessel while biasing the distal “rats tail” into a stable position in the smaller target vessel.
[0012] The preferred implantation process requires a percutaneous puncture to access the subclavian vein. The implanted pulse generator (IPG) will be implanted in a subcutaneous pocket nearby. A guide catheter having a shaped tip is navigated along the subclavian vein using a guidewire. The catheter and wire pass through the brachiocephalic vein in to the ostium of the left pericardiophrenic vein. Normal contrast venography techniques are used to illuminate and access this location. The guidewire is inserted several centimeters into the left pericardiophrenic vein and the mouth of the guide catheter is passed into the ostium of the left pericardiophrenic vein. Next the stimulation lead is delivered to a target location through the guide catheter over the guidewire alone or with the use of a stylet. When the electrodes are well positioned near the phrenic nerve target location the stylet or guidewire is removed and the optional stabilizing or finishing guidewire wire is exchanged and inserted into the lead body. Relative traction between the finishing guide wire and the guide sheath allows for the smooth removal of the guide catheter without dislodging the lead. In essence the “rats tail” remains biased and stationary in the left pericardiophrenic vein as the lead “relaxes” and assumes its natural low mechanical energy state while the guide catheter is removed. Withdrawal of the finishing wire if used or the guidewire or stylet activates the complementary shaped curves of the lead. As the curves bend and unfurl into contact with the larger brachiocephalic vein the most distal tip of the of the lead in the smaller vessel becomes stabilized. Next the proximal connector of the lead is coupled to the IPG. The IPG provides stimulation that completes the implantation method and the method of therapy.
Brief Description of the Drawings
[0013] Identical reference numerals indicate identical features throughout the figures of the drawing, wherein:
[0014] FIG. 1 depicts the implanted system;
[0015] FIG. 2 depicts the lead device;
[0016] FIG. 3 depicts a step in method used to implant the device;
[0017] FIG. 4 depicts the lead in position in the target vessel with the electrodes positioned at the target location.
Detailed Description of the Invention
[0018] Stimulation Regime
[0019] The applicant has incorporated a utility patent reference that discloses in detail a medical device (IPG) that can detect and treat CSR and other forms of breathing disorders by the transvenous electrical stimulation of the phrenic nerve.
[0020] For purposes of this disclosure it is sufficient to understand that the disclosed technique uses electrical stimulation of one phrenic nerve to arrest or still the motion of one hemidiaphram of the patient. This process lowers the observed breathing rate post therapy and over time drives the blood gases to an improved state of oxygen saturation and carbon dioxide elimination.
[0021] The implanted pulse generator (IPG) 12 has the ability to detect the respiration process in real time. Preferably impedance plesthmography is used to detect both the rate of respiration and the turning points within a single breath. It is anticipated that the companion IPG 12 includes an impedance plethysmograph that emits minute electrical pulses between electrodes on a measurement lead system (not shown in the present figures). These impedance signals are used to measure the volume of the lung and rate of change of volume of the lung.
[0022] The phrenic nerve stimulation therapy is provided after the start of a breath but before the natural end of the breath. The magnitude of the stimulation is sufficient to arrest the motion of the diaphragm. By essentially stopping the breathing for a moment the overall duration of the breath is extended. This breath hold process lowers the observed rate of breathing of at least one lung.
[0023] This stimulation therapy may be supplied to each breath for a series of breaths or on a less frequent basis. The stimulation may be supplied in response to a detected episode of CSR or it may be provided to prevent progression to CSR. For example, stimulation may be initiated upon the detected occurrence of CSR. Alternatively an activity sensor may report that the patient is supine and at rest and this set of criteria may be necessary and sufficient to invoke therapeutic stimulation. Regardless of the specific intervention criteria, the IPG will delivery the appropriate amount of energy to still the breath, via the transvenous stimulation lead.
[0024] System Architecture
[0025] FIG. 1 depicts the overall architecture and context of the therapy where the lead 10 coupled to an implanted pulse generator 12. The lead is inserted through the brachiocephalic vein 14 into the ostium 16 of the left pericardiophrenic vein 18. In this chronic condition the two electrodes 20 and 22 can deliver electrical stimulation to the phrenic nerve 24, which courses parallel to the vein 18 in this target vessel at this target location. This half of the branching phrenic nerve 24 terminates in the hemidiaphram 26 as indicated by the innervations depicted at location 28. The nerve innervations excite the muscles of the hemidiaphram which move downward as indicated by motion arrows 32 to produce inspiration followed by upward motion as indicated by motion arrow 30 to produce expiration. Together the motion arrows represent rhythmic respiration. For purposes of orientation other familiar anatomic structures are seen but not labeled in the figure.
[0026] In summary after implantation the lead 10 system delivers electrical stimulation to the phrenic nerve to arrest diaphragm 26 motion by the delivery of electrical energy after the onset of inspiration indicated by motion arrow 32 in the figure and the electrical energy delivered is sufficient to pause that diaphragm motion. In this fashion the lead 10 system and the IPG 12 are used for stimulating the phrenic nerve 24 of a patient to treat defects in respiration.
[0027] Stimulation Lead
[0028] FIG. 2 depicts the lead system 10 in isolation. The lead is best considered by dividing it up into various segments. The most distal segment 50 takes the form of a narrow taper. This “rats tail” is coupled to a stimulation segment 58 that includes a first electrode 22 and a second electrode 20. Although the preferred exemplary embodiment shows two electrodes, other numbers of electrodes are operable and desirable in some situations. The electrode placement on the leads seen in the figures is desirable because to the extent possible it is desired to have the stimulation current path transect the longitudinal fibers of the phrenic nerve 24 at the target location. It has been determined experimentally that this orientation reduces thresholds for stimulation of the nerve.
[0029] Next, an intermediate shaped segment is shown at numeral 60. The shaped segment includes two or more bends or loops or curves. The bend curve 48 lies in the XZ plane in the figure. The bend curve 46 rises out of the XZ plane in the Y direction. Preferably the axis of the distal segment 50 makes an included angle of about 15 degrees with respect to the XZ plane.
[0030] The most proximal segment includes a connector pin assembly 52 that allows conductors within the lead to communicate with the two electrodes. For clarity the conductors are not shown. The construction of the conductors is well known in this art and need not be shown in detail. Preferably and overall the elongate portion 54 of the shaped segment 60 and the distal segment 50 are not coplanar and the major axis of the elongate portion 54 and major axis of the distal segment 50 are not coaxial. These geometric constraints place the elongate segment 54 and the distal segment 50 in separate planes and the major axes of these sections of the lead are not collinear.
[0031] FIG. 2 shows the lead 10 in isolation in its low stress state. The lead has a natural neutral bias in the figure and the lead structure and shape gives rise to a friction zone caused by a in-plane deflection of the lead around first primary radius of bend curve 48 and a secondary radius of bend curve 46. In use the curvilinear structures will permit the stable positioning of the lead body in the brachiocephalic vein and permit entry of the stimulation segment into the ostium of the left pericardiophrenic vein and stabilize the electrodes at the target location.
[0032] The lead may also have a through lumen to accept a guide wire 56 as depicted in the figure passing into the connector 52 pin and traveling beyond the distal tip and emerging at reference numeral 56. As an alternative, a stylet lumen may be located within the lead to permit the use of a stylet to stiffen the lead. It may also be desirable to have a mechanical stop in the stylet or guide wire lumen to accept a “finishing wire”. This optional finishing wire can be used to supply a force to the lead to keep it in position as the guide catheter is removed. In general the finishing wire is of slightly larger diameter and it bottoms out at a location near but still proximal of the electrode and shaped segments of the lead. Pulling on the guide catheter while pushing on the finishing wire at the same time prevents the lead to guide catheter friction from dislodging or moving the electrodes from their preferred location.
[0033] Method of Implantation
[0034] FIG. 3 is an enlarged portion of part of FIG. 1 designated by numeral 34 on FIG. 1 . The brachiocephalic vein 14 and the branching left pericardiophrenic vein 18 are shown in isolation. The figure illustrates a method of implanting a lead in a small vein 18 that branches off from a large vein 14. The process begins with a “percutaneous stick” to access a large vein connecting to the brachiocephalic vein. A sharp hollow needle trocar enters the vein and a guidewire is advanced through the trocar into the vessel. The trocar is withdrawn over the wire and replaced with a sheath which is passed into the vessel. Next a guide wire and guide catheter of the type having a distal curve are navigated to the ostium 16 of the left pericardiophrenic vein. The curved tip for the guiding catheter is introduced in to this small vein. Venographic imaging technologies such as contrast injection and biplane fluoroscopy are used to locate the ostium 16. With both the guide wire and guide catheter in the small vein the lead 10 may be passed over the wire into the vein. Under contrast imaging and temporary stimulation the best spot for activating the phrenic nerve is located. This defines the target location. Next the guidewire and guiding catheter are carefully removed while holding the lead in position with the optional finishing wire if present. The finishing wire if used compensates for the friction between the guide catheter 60 and the lead 10 which would otherwise causes the guide catheter to tend to drag the lead out of position as the guide catheter is removed.
[0035] Lead Interactions
[0036] Turning to FIG. 4 once again there is a shown an enlarged section of FIG. 1 indentified in that figure by reference numeral 34. FIG. 4 shows the lead 10 delivered through a guide sheath 40. A stylet or guidewire (GW) may be inserted into the lead 10 to straighten and stiffen the structure. Once the lead enters the target vessel the stylet may be removed and the lead adopts its low stress state in the vessel. In this figure the biasing mechanism 46 is shown in contact with the walls of the vessel 18. The bend 48 lies in a single plane in contact with the wall of vessel 14. The bend or shape 46 exerts a force against the ostium 16 to help anchor the electrodes and stimulation segment in the smaller target vessel 18.
[0037] Steroid eluting features may be provided on portions of the lead system to reduce inflammation associated with the placement of the leads. Other coatings maybe used to enhance or reduce friction to help stabilize the lead.
Claims
What is claimed is:
1. A method of treating a patient comprising:
placing a lead in a brachiocephalic vein and proximate a left pericardiophrenic vein, the lead having at least one electrode;
positioning the at least one electrode within the left pericardiophrenic vein and adjacent a left phrenic nerve;
implanting a pulse generator for supplying electrical stimulation energy to said phrenic nerve;
delivering the electrical stimulation energy at a time after an onset of a breath, whereby the electrical stimulation energy delivered is configured to:
arrest motion of a hemidiaphragm innervated by said phrenic nerve; and
extend a duration of the stimulated breath.
2. The method of claim 1, wherein the electrical stimulation energy is delivered such that a right phrenic nerve remains under normal physiologic control.
3. The method of claim 1, wherein the electrical stimulation energy is delivered via a stimulation pulse having a shape wherein an amplitude of the electrical stimulation energy increases over time within the pulse.
4. The method of claim 1, wherein the electrical stimulation energy is delivered via a stimulation pulse having a shape wherein an amplitude increases over time and then decreases over time within the pulse.
5. The method of claim 1, wherein the electrical stimulation energy is delivered via a series of stimulation pulses that have increasing amplitudes over a period of time.
6. The method of claim 1, wherein the electrical stimulation energy is delivered episodically without regard to sensed conditions.
7. The method of claim 1, wherein the lead comprises a tapered distal tip.
8. The method of claim 1, wherein the lead comprises a lead body and the lead body forms a guidewire lumen.
9. The method of claim 1, wherein the lead comprises a drug eluting coating.
10. The method of claim 1 further comprising a step of inserting a guidewire at least one centimeter into the left pericardiophrenic vein and advancing the lead over the guidewire.
11. The method of claim 1, comprising positioning a bend of the lead in contact with an ostium of the left pericardiophrenic vein.
12. The method of claim 1, comprising positioning a first bend of the lead in contact with a wall of the brachiocephalic vein.
13. The method of claim 12, comprising positioning a second bend of the lead in contact with a wall of the left pericardiophrenic vein.
14. The method of claim 1 comprising:
delivering the electrical stimulation energy at a magnitude of stimulation to
avoid incidental stimulation of cardiac tissue.
15. The method of claim 14, wherein the lead exerts a bias force to retain a distal tip of the lead substantially immobile.
16. The method of claim 14, comprising positioning a first bend of the lead in contact with a wall of the brachiocephalic vein.
17. The method of claim 16, comprising positioning a second bend of the lead in contact with a wall of the left pericardiophrenic vein.
18. The method of claim 14, comprising positioning a bend of the lead in contact with an ostium of the left pericardiophrenic vein.
Patent Citations (107)
| Patent | Date | Inventor | Cited By |
|---|---|---|---|
| US4129125(A) | 1978-12-01 | Lester et al. | Applicant |
| US4169479(A) | 1979-10-01 | Muto | Applicant |
| US4827935(A) | 1989-05-01 | Geddes et al. | Applicant |
| US4830008(A) | 1989-05-01 | Meer | Applicant |
| US5056519(A) | 1991-10-01 | Vince | Applicant |
| US5146918(A) | 1992-09-01 | Kallok et al. | Applicant |
| US5170802(A) | 1992-12-01 | Mehra | Applicant |
| US5184621(A) | 1993-02-01 | Vogel et al. | Applicant |
| US5265604(A) | 1993-11-01 | Vince | Applicant |
| US5483969(A) | 1996-01-01 | Testerman et al. | Applicant |
| US5485851(A) | 1996-01-01 | Erickson | Applicant |
| US5531781(A) | 1996-07-01 | Alferness et al. | Applicant |
| US6006134(A) | 1999-12-01 | Hill et al. | Applicant |
| US6132384(A) | 2000-10-01 | Christopherson et al. | Applicant |
| US6212435(B1) | 2001-04-01 | Lattner et al. | Applicant |
| US6266564(B1) | 2001-07-01 | Hill et al. | Applicant |
| US6360740(B1) | 2002-03-01 | Ward et al. | Applicant |
| US6415183(B1) | 2002-07-01 | Scheiner et al. | Examiner |
| US6449507(B1) | 2002-09-01 | Hill et al. | Applicant |
| US6456863(B1) | 2002-09-01 | Levin et al. | Applicant |
| US6463327(B1) | 2002-10-01 | Lurie et al. | Applicant |
| US6532388(B1) | 2003-03-01 | Hill et al. | Applicant |
| US6537228(B1) | 2003-03-01 | Lambert | Applicant |
| US6542774(B2) | 2003-04-01 | Hill et al. | Applicant |
| US6587726(B2) | 2003-07-01 | Lurie et al. | Applicant |
| US6589188(B1) | 2003-07-01 | Street et al. | Applicant |
| US6641542(B2) | 2003-11-01 | Cho et al. | Applicant |
| US6684101(B2) | 2004-01-01 | Daum | Applicant |
| US6714823(B1) | 2004-03-01 | De Lurgio et al. | Applicant |
| US6718208(B2) | 2004-04-01 | Hill et al. | Applicant |
| USRE38705(E) | 2005-02-01 | Hill et al. | Applicant |
| US6881192(B1) | 2005-04-01 | Park | Applicant |
| US6890306(B2) | 2005-05-01 | Poezevera | Applicant |
| US6928324(B2) | 2005-08-01 | Park et al. | Applicant |
| US6934583(B2) | 2005-08-01 | Weinberg et al. | Applicant |
| US6937903(B2) | 2005-08-01 | Schuler et al. | Applicant |
| US6964641(B2) | 2005-11-01 | Cho et al. | Applicant |
| US7025730(B2) | 2006-04-01 | Cho et al. | Applicant |
| US7070568(B1) | 2006-07-01 | Koh | Applicant |
| US7077132(B2) | 2006-07-01 | Berthon-Jones | Applicant |
| US7082331(B1) | 2006-07-01 | Park et al. | Applicant |
| US7094207(B1) | 2006-08-01 | Koh | Applicant |
| US7155278(B2) | 2006-12-01 | King et al. | Applicant |
| US7179229(B1) | 2007-02-01 | Koh | Applicant |
| US7184829(B2) | 2007-02-01 | Hill et al. | Applicant |
| US7200442(B1) | 2007-04-01 | Koh et al. | Applicant |
| US7212862(B2) | 2007-05-01 | Park et al. | Applicant |
| US7223244(B1) | 2007-05-01 | Koh | Applicant |
| US7225019(B2) | 2007-05-01 | Jahns et al. | Applicant |
| US7225021(B1) | 2007-05-01 | Park et al. | Applicant |
| US7245971(B2) | 2007-07-01 | Park et al. | Applicant |
| US7269457(B2) | 2007-09-01 | Shafer et al. | Applicant |
| US7269459(B1) | 2007-09-01 | Koh | Applicant |
| US7277757(B2) | 2007-10-01 | Casavant et al. | Applicant |
| US7340302(B1) | 2008-03-01 | Falkenberg et al. | Applicant |
| US7357775(B1) | 2008-04-01 | Koh | Applicant |
| US7361146(B1) | 2008-04-01 | Bharmi et al. | Applicant |
| US7363086(B1) | 2008-04-01 | Koh et al. | Applicant |
| US7371220(B1) | 2008-05-01 | Koh et al. | Applicant |
| US7628801(B2) | 2009-12-01 | Westlund et al. | Applicant |
| US7647115(B2) | 2010-01-01 | Levin et al. | Applicant |
| US7747323(B2) | 2010-06-01 | Libbus et al. | Applicant |
| US7787946(B2) | 2010-08-01 | Stahmann et al. | Applicant |
| US8086314(B1) | 2011-12-01 | Kieval | Applicant |
| US8131372(B2) | 2012-03-01 | Levin et al. | Applicant |
| US8200336(B2) | 2012-06-01 | Tehrani et al. | Applicant |
| US8255056(B2) | 2012-08-01 | Tehrani | Applicant |
| US8280513(B2) | 2012-10-01 | Tehrani et al. | Applicant |
| US8290595(B2) | 2012-10-01 | Kieval et al. | Applicant |
| US8348941(B2) | 2013-01-01 | Tehrani | Applicant |
| US8463401(B2) | 2013-06-01 | Jones et al. | Applicant |
| US2001/0003799(A1) | 2001-06-01 | Boveja | Applicant |
| US2002/0165535(A1) | 2002-11-01 | Lesh et al. | Applicant |
| US2003/0195571(A1) | 2003-10-01 | Burnes et al. | Examiner |
| US2004/0088015(A1) | 2004-05-01 | Casavant et al. | Examiner |
| US2005/0043765(A1) | 2005-02-01 | Williams et al. | Examiner |
| US2005/0085734(A1) | 2005-04-01 | Tehrani | Applicant |
| US2005/0085865(A1) | 2005-04-01 | Tehrani | Applicant |
| US2005/0085866(A1) | 2005-04-01 | Tehrani | Applicant |
| US2005/0085867(A1) | 2005-04-01 | Tehrani et al. | Applicant |
| US2005/0085868(A1) | 2005-04-01 | Tehrani et al. | Applicant |
| US2005/0085869(A1) | 2005-04-01 | Tehrani et al. | Applicant |
| US2005/0197588(A1) | 2005-09-01 | Freeberg | Applicant |
| US2005/0288729(A1) | 2005-12-01 | Libbus et al. | Applicant |
| US2005/0288759(A1) | 2005-12-01 | Jones et al. | Applicant |
| US2006/0030894(A1) | 2006-02-01 | Tehrani | Applicant |
| US2006/0036294(A1) | 2006-02-01 | Tehrani | Applicant |
| US2006/0122662(A1) | 2006-06-01 | Tehrani et al. | Applicant |
| US2006/0142815(A1) | 2006-06-01 | Tehrani et al. | Applicant |
| US2006/0149334(A1) | 2006-07-01 | Tehrani et al. | Examiner |
| US2006/0155341(A1) | 2006-07-01 | Tehrani et al. | Applicant |
| US2006/0167523(A1) | 2006-07-01 | Tehrani et al. | Applicant |
| US2006/0229677(A1) | 2006-10-01 | Moffitt et al. | Applicant |
| US2006/0247729(A1) | 2006-11-01 | Tehrani et al. | Applicant |
| US2006/0247750(A1) | 2006-11-01 | Seifert et al. | Applicant |
| US2007/0021795(A1) | 2007-01-01 | Tehrani | Applicant |
| US2008/0154330(A1) | 2008-06-01 | Tehrani et al. | Applicant |
| US2008/0161878(A1) | 2008-07-01 | Tehrani et al. | Applicant |
| US2008/0167695(A1) | 2008-07-01 | Tehrani et al. | Applicant |
| US2008/0177347(A1) | 2008-07-01 | Tehrani et al. | Applicant |
| US2008/0183239(A1) | 2008-07-01 | Tehrani et al. | Applicant |
| US2008/0183240(A1) | 2008-07-01 | Tehrani et al. | Applicant |
| US2008/0183264(A1) | 2008-07-01 | Bly | Examiner |
| US2008/0188903(A1) | 2008-08-01 | Tehrani et al. | Applicant |
| US2008/0188904(A1) | 2008-08-01 | Tehrani et al. | Applicant |
| EP1588735(A1) | 2005-10-01 | Applicant | |
| WO2008092246(A1) | 2008-08-01 | Applicant |
Non-Patent Literature (45)
- Canadian Office Action dated May 26, 2015 for corresponding Canadian Application No, 2,630,211, filed May 16, 2008.Applicant
- Canadian Office Action dated Jan. 4, 2016 for corresponding Canadian Application No. 2,865,410, filed Sep. 14, 2014.Applicant
- Canadian Office Action dated Nov. 17, 2016 for corresponding Canadian Application No. 2,865,410.Applicant
- International Search Report of International Application PCT/US2006/044788 (dated Aug. 15, 2007), 3pp.Applicant
- Written Opinion of the International Searching Authority of International Application PCT/US2006/044788 (dated Apr. 12, 2007), 3 pp.Applicant
- International Preliminary Report on Patentability of International Application PCT/US2006/044788 (dated May 20, 2008), 4pp.Applicant
- Redline, Susan et al., Beyond the Fat Boy, Journal of Applied Physiology 2005, vol. 99: pp. 1243-1244.Applicant
- Esler, Murray et al., Is Obstructive Sleep Apnea the Cause of Sympathetic Nervous Activation in Human Obesity?, Journal of Applied Physiology 2006, vol. 100, pp. 11-12.Applicant
- Caples, Sean M. et al., Influence of Cardiac Function and Failure on Sleep-Disordered Breathing, Journal of Applied Physiology 2005, vol. 99, pp. 2433-2439.Applicant
- Punjabi, Naresh M. et al., Disorders of Glucose Metabolism in Sleep Apnea, Journal of Applied Physiology 2005, vol. 99, pp. 1998-2007.Applicant
- Leuenberger, Urs A., et al., Hypoxia Augments Apnea-Induced Peripheral Vasoconstriction in Humans, Journal of Applied Physiology 2001, vol. 90, pp. 1516-1522.Applicant
- Oliven, Arie, et al., Upper Airway Response to Electrical Stimulation of the Genioglossus in Obstructive Sleep Apnea, Journal of Applied Physiology 2003, vol. 95, pp. 2023-2029.Applicant
- Parati, Gianfranco et al., Sleep Apnea: Epidemiology, Pathophysiology, and Relation to Cardiovascular Risk, Am Journal Physiological Society 2007, vol. 293, pp. R1671-R1683.Applicant
- Gottfried, Stewart B. et al., Effects of Phrenic Stimulation on Upper Airway Resistance in Anesthetized Dogs, Am Physiological Society 1983, 0161-7567/83, pp. 419-425.Applicant
- Planas, Roque F. et al., Diaphragmatic Pressures: Transvenous vs. Direct Phrenic Nerve Stimulation, Am Physiological Society 1985, 0161-7568/85, pp. 269-273.Applicant
- Series, F. et al., Site of Phrenic Nerve Stimulation-Induced Upper Airway Collapse: Influence of Expiratory Time, Journal of Applied Physiology 2002, vol. 92, pp. 665-671.Applicant
- Kingma, John G. Jr. et al., Neuromodulation Therapy Does Not Influence Blood Flow Distribution or Left-Ventricular Dynamics During Acute Myocardial Ischemia, Autonomic Neuroscience: Basic and Clinical 91 (2001) [[/47-54.Applicant
- Linderoth, Bengt, MD, PHD et al., Mechanisms of Spinal Cord Stimulation in Painful Syndromes: Role of Animal Models, American Academy of Pain Medicine, vol. 7, No. S14-S26, 2006.Applicant
- Tanaka, Satoshi et al., Mechanims of Sustained Cutaneous Vasodilation Induced by Spinal Cord Stimulation, Autonomic Neuroscience: Basic and Clinical 114 (2004) pp. 55-60.Applicant
- Lorenzi-Filho, Geraldo et al., Cheyne-Stokes Respiration in Patients with Congestive Heart Failure: Causes and Consequences, Clinics 2005; 60(4):333-44.Applicant
- Brack, Thomas, Cheyne-Stokes Respiration in Patients with Congestive Heart Failure, Swiss Med Wkly 2003; 133:605-610, www.smw.ch.Applicant
- Yumino, Dai et al., Central Sleep Apnea and Cheyne-Stokes Respiration, Proceedings of the American Thoracic Society, 2008, vol. 5, pp. 226-236.Applicant
- Garrido-Garcia, H. et al., Treatment of Chronic Ventilatory Failure Using a Diaphragmatic Pacemaker, Spinal Cord (1998) 36, 310-314.Applicant
- Diedrichs, Holger et al., Symptomatic Relief Precedes Improvement of Myocardial Blood Flow in Patients Under Spinal Cord Stimulation, BioMed Central, 2005, pp. 1-7.Applicant
- Kaneko, S. et al., A New Approach to Respiratory Assist for Phrenic Nerve Paralysis, Trans Am Soc. Artif Intern Organs, 1985, vol. XXXI, pp. 301-304.Applicant
- Macintyre, Neil R. MD, Setting the Frequency-Tidal Volume Pattern, www.rcjournal.com/contents/03.02/03.02.0266.asp.Applicant
- Kohnlein, T. et al., Central Sleep Apnea Syndrome in Patients with Chronic Heart Disease: A Critical Review of the Current Literature, Thorax 2002; 57:547-554.Applicant
- Javaheri, Shahrokh, MD, Central Sleep Apnea in Congestive Heart Failure: Prevalence, Mechanisms, Impact, and Therapeutic Options, Seminars in Respiratory and Critical Care Medicine, 2005, vol. 26, No. 1.Applicant
- Dobelle, William H., Use of Breathing Pacemakers to Suppress Intractable Hiccups of up to Thirteen Years Duration, ASAIO Journal 1999, pp. 524-525.Applicant
- Series, Frederic, Assessment of Upper Airway Dynamics in Awake Patients with Sleep Apnea Using Phrenic Nerve Stimulation, Am Journal Respir Crit Care Med, 2000, vol. 162., pp. 795-800.Applicant
- Bilgutay, A.M. et al., Augmented Ventilation by Synchronous Phrenic Nerve Stimulation, Trans. Amer. Soc. Artif. Int. Organs, 1970, vol. XVI, pp. 213-217.Applicant
- Yasuma, Fumihiko et al., Eight-Year Follow-Up Study of a Patient with Central Alveolar Hypoventilation Treated with Diaphragm Pacing, Respiration, 1998; 65:313-316.Applicant
- Handa, Y. et al., Basic Studies on Electrophrenic Respiration Part 2—Assisted Ventilation by the Synchronous Electrophrenic Respirator, Medical and Biological Engineering, Jul. 1976.Applicant
- Kimura, M. et al., A Heart-Rate-Responsive Diaphragm Pacemaker, Med. & Biol. Eng. & comput., 1987, 25, 458-462.Applicant
- Kimura, M. et al., Heart Rate and Body Temperature Sensitive Diaphragm Pacing, Med. & Biol. Eng. & Comput., 1992, 30, 155-161.Applicant
- Kimura, M. et al., Additive to an RF-Coupled Phrenic Nerve Stimulator Implant to Provide Outward Transmission of Body Temperature, Med. & Biol. Eng. & compt. 1986, 24, 659-661.Applicant
- Taira, Takaomi, MD, PHD et al., Phrenic Nerve Stimulation for Diaphragm Pacing with a Spinal Cord Stimulator, Elsevier Science, Surg Neurol, 2003; 59:128-32.Applicant
- Chatfield, Paul O. et al., Role of Pulmonary Proprioceptive Reflexes in Suppression of Spontaneous Breathing During Electrophrenic Respiration, Dept. of Physiology, Harvard Medical School, and Dept. of Physiology, Harvard School of Public Health, vol. 163.Applicant
- Sarnoff, Stanley J. et al., Electrophrenic Respiration. III. Mechanism of the Inhibition of Spontaneous Respiration, Dept. of Physiology, Harvard School of Public Health, 1948, vol. 155, pp. 203-207.Applicant
- Sarnoff, Stanley J. et al., Electrophrenic Respiration IV. The Effectiveness of Contralateral Ventilation During Activity of One Phrenic Nerve, Dept. of Physiology, Harvard School of Public Health, 1949, pp. 929-937.Applicant
- Stemmer, Edward A. MD et al., Diaphragmatic Pacing in the Treatment of Hypoventilation Syndrome, Journal of Thoracic and Cardiovascular Surgery, Sol. 54, No. 5, 1967, pp. 649-657.Applicant
- Furman, Seymour, MD et al., Transvenous Stimulation of the Phrenic Nerves, Journal of Thoracic and Cardiovascular Surgery, Sol. 62, No. 5, 1971, pp. 743-751.Applicant
- Aiyar, Harish et al., Diaphragm Pacing for Chronic Respiratory Insufficient, CRC Press, LLC, 2001, Chapter 9.Applicant
- Canadian Office Action dated Jul. 12, 2017 for corresponding Canadian Application No. 2,865,410, filed Sep. 26, 2014.Applicant
- Canadian Office Action dated Jun. 29, 2018 for corresponding Canadian Application No. 2,865,410, filed Sep. 26, 2014.Applicant